DV
Dividend Vision

LOBEF — Lobe Sciences Ltd

Lobe Sciences Ltd (LOBEF)

Total return is 1200.0% over the past 6.9 years, 1009.2 points ahead of SPY at 190.8%. Its deepest 1-year drawdown was 95.6%.

Lobe Sciences Ltd. is a Canadian biopharmaceutical company focused on developing lipid-based treatments for orphan and rare diseases, including a medical food product called Altemia® MF for managing deficiencies in sickle cell disease. The company was founded in 2018 and is headquartered in Vancouver. Distribution information is not currently available.

LOBEF key facts

Asset type
Stock
Asset class
Equity
Distribution frequency
None
Last close
$0.0052
Market cap
$1,602,547
Average volume
35800.0
Beta
-0.064
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.03